Introduction
in people with a reduced glomerular filtration rate (GFR), especially in older and malnourished patients. [5] [6] [7] Several equations have been developed to estimate GFR. [8] [9] [10] [11] The most commonly used is the abbreviated equation from the Modification of Diet in Renal Disease (MDRD) study, which was developed by applying linear regression analysis to data from enrollees in the MDRD study. 8 Calculation of an estimated GFR (eGFR) is widely accepted as the best method to measure renal function and define the stage of CKD; yet, in clinical practice beyond nephrology, it is not widely utilized.
12 Surprisingly, the eGFR equation is routinely used to identify CKD in people who participate in a self-pay standard medical screening program in health management centers in Taiwan. Since the primary purpose of such screening programs in health management centers is to detect illnesses while they are still in the early stages, the use of eGFR to identify patients with CKD during health assessment seems strongly justified. The routine assessment of kidney disease includes blood urea nitrogen (BUN) and serum Cr levels, urinalysis, and kidney ultrasound examination. This study aimed to determine the difference between routine assessment and the eGFR method in identifying patients with CKD in health management centers. Study subjects who had stages 3-5 CKD according to the abbreviated MDRD (aMDRD) eGFR equation but who had normal results from routine assessments were classified as the "underrecognized group". To identify the risk of renal failure in study subjects with normal results of routine assessment of kidney disease, episodes of renal failure that had occurred within 2 years of standard medical screening were evaluated in all study subjects with stages 3-5 CKD by eGFR.
Methods
All participants in the self-pay standard medical screening program in the health management center at Taichung Veterans General Hospital, Taiwan, between January 2003 and November 2006 were enrolled in the study. The health management center attracted paying participants from all over central Taiwan because of its known quality services. All subjects participated in a standard medical screening protocol, including a medical interview, comprehensive physical examination, chest X-ray, resting electrocardiography, echocardiography, abdominal ultrasound, upper gastrointestinal endoscopy, lower gastrointestinal endoscopy, urine and stool analysis, blood biochemistry, hematology analysis, thyroid hormone study, and tumor marker screening.
Abnormal BUN was defined as a BUN over the upper limit of normal (25 mg/dL). Abnormal Cr was defined as serum Cr over the upper limit of normal (1.4 mg/dL). The same cutoff values of serum Cr were used for males and females. Abnormal urinalysis was defined as the presence of proteinuria (protein +/-to ++++), hematuria (red blood cells > 2 per high-powered field), pyuria (white blood cells > 2 per high-powered field in males or > 5 per highpowered field in females), bacteriuria, occult blood, or glycosuria by spot urine microscopic and chemical examinations. Abnormal kidney ultrasound was defined as the presence of calcification or stones, cysts, nodules, hydronephrosis, increased echogenicity, abnormal kidney size (> 13 cm or < 10 cm) or a single kidney.
We ). 8, 12 Study subjects who had an eGFR less than 60 mL/min/1.73 m 2 but with normal results from routine assessments were classified as "under-recognized CKD". Two methods were used to detect episodes of renal failure in study subjects with stages 3-5 CKD by eGFR. The first method was a review of the medical records and the second method was interviews by phone calls. An episode of renal failure was defined as renal failure requiring dialysis within 2 years after standard medical screening.
The prevalence of CKD in this study was minimally affected by missing data. Only 3 participants were excluded for missing records of medical interviews and physical examinations. Another 28 patients who had undergone regular dialysis or who were kidney transplant recipients were also excluded. All participants had provided signed consent for processing the data generated from medical screening. Ethics reviews were processed and approved by the Ethics Committee of Taichung Veterans General Hospital (IRB TCVGH No: C08052).
Participants' characteristics were summarized descriptively (using mean ± standard deviation for continuous variables and counts and percentages for categorical variables). Statistical analysis was performed with SPSS version 13 (SPSS Inc., Chicago, IL, USA 
Results
The characteristics of all study subjects are summarized in Table 1 . Of the total cohort, 909 subjects (5.7%) had a history of diabetes mellitus and 3,372 (21.3%) a history of hypertension; 489 (3.1%) had abnormal serum Cr levels and 317 (2.0%) had abnormal BUN levels. Abnormal kidney ultrasound results were found in 2,626 (16.6%), while 3,698 (23.4%) had at least 1 abnormal urine analysis result. A total of 1,060 (6.7%) subjects had proteinuria over 30 mg (1 +) and 664 (4.2%) had trace proteinuria (+ /-), 2,521 (15.9%) subjects had hematuria, 3,580 (22.6%) subjects had pyuria, and 221 (1.4%) subjects had glycosuria. Compared to males, females had significantly more hematuria (23.1% vs. 10.9%, p = 0.024) and pyuria (38% vs. 11.8%, p < 0.001). Among subjects with abnormal serum Cr or BUN levels, 139 of 537 subjects (25.9%) had normal urine analysis results. In total, 28.4% of study subjects were identified as having a kidney problem by routine clinical assessment and were referred to nephrologists.
Using the aMDRD equation to estimate GFR, 1,319 (8.3%) subjects had stage 3A CKD and 188 (1.9%) subjects had stage 3B CKD ( Table 2 ). Another 54 (0.3%) subjects had stage 4 CKD and 32 (0.2%) subjects had stage 5 CKD. Overall, 1,593 (10.7%) study subjects including 1,002 (10.8%) males and 591 (9%) females, were diagnosed as stages 3-5 CKD. The overall prevalence of stages 3-5 CKD among study subjects older than 60 years was 29.3% ( Figure 1 ). The prevalence of stages 3-5 CKD increased with age. Table 2 shows the range, mean, and mode of serum Cr in all subjects with stages 3-5 CKD. Female subjects had lower levels of the range, mean, and mode of serum Cr than males. All 86 patients who were identified as stage 4 or 5 CKD via the aMDRD equation had serum Cr levels higher than 1.4 mg/dL, and were found to have kidney disease via the standard medical screening program. The serum Cr level of all subjects with stage 3 CKD was 1.0-2.6 mg/dL. All female Renal failure in under-recognized stage 3B CKD (Table 3) .
Among subjects with stages 3-5 CKD, 921 (57.8%) subjects (69.7% males, 37.7% females) had normal urinalysis results. Since all subjects with stages 4 and 5 CKD had abnormal serum Cr levels, we evaluated the results of routine assessments in subjects with stage 3 CKD. In 188 subjects with stage 3B CKD, 78 (41.5%) subjects (46.7% males, 32.4% females) had normal urinalysis results. Of 1,507 subjects with stage 3 CKD identified by the aMDRD equation, 470 subjects had abnormal serum Cr levels with or without abnormal BUN levels, while 734 (48.7%) had normal results for serum Cr and BUN levels, urinalysis and kidney ultrasound (Table 4) . These 734 (4.6%) study subjects out of the total of 15,817 were then classified as under-recognized.
All 1,593 study subjects with stages 3-5 CKD identified by the aMDRD equation were evaluated via medical records and interviews. Eighteen subjects were lost at this cross-sectional follow-up. In total, 32 episodes of renal failure requiring dialysis within 2 years after standard medical screening were found in the remaining 1,575 study subjects. Table 5 demonstrates the episodes of renal failure in all subjects with stages 3-5 CKD by eGFR. Six (18.8%) subjects with stage 5 CKD developed renal failure. Two (3.7%) subjects with stage 4 CKD developed renal failure. Renal failure in under-recognized stage 3B CKD Stage 5 CKD and stage 3B CKD with normal routine clinical assessment had a similar risk of renal failure and this risk was significantly higher than that for the other CKD groups (Table 5) .
Discussion
In the past 2 decades, the kidney disease screening program has changed in Japan and many countries. 4, 13 The program started with urinalysis and measurements of serum Cr and estimation of GFR by equation were added later. Currently, formulaic estimations of GFR are widely used by nephrologists, but these estimations have many pitfalls. Although eGFR reporting could promote identification of more cases of CKD, it is also possible that attention and resources could be directed towards patients falsely identified as having CKD or with early CKD. Application of eGFR without adjustment for the effects of racial disparity, age and sex may also result in over-diagnosis of CKD. 14, 15 Although increasing the rate of patient referral to nephrologists on the basis of eGFR could increase costs and use of medical resources, nephrologists obtain better blood pressure control and slower progression of renal function than non-nephrologists. 16, 17 Moreover, the purpose of self-pay standard medical screening programs in health management centers is to evaluate how healthy a person is and help minimize the barriers to health care. The routine health assessment tools for identifying kidney disease in most management centers in Taiwan are serum Cr and BUN levels, urinalysis, and kidney ultrasound. The eGFR equation is not included. In our cohort, 28.4% of study subjects were identified as having a kidney problem by the above routine assessment tools and were referred to nephrologists. However, only a small percentage of subjects had abnormal results for serum Cr levels (3.1%) and BUN levels (2.0%), and proteinuria over 30 mg (6.7%). The percentage of proteinuria in our study is similar to a previous report from a nationally representative survey in Taiwan. 4 Although 22.6% of subjects had pyuria and 15.9% had hematuria, it is not surprising that female subjects had significantly higher percentages of hematuria and pyuria than male subjects. The use of urinalysis is not sufficient to screen for kidney disease. A significant proportion of subjects with either stages 3-5 CKD or abnormal serum Cr/BUN levels had normal urinalysis results. On the other hand, many subjects with . Two-year cumulative renal survival in study subjects with an estimated glomerular filtration rate < 60 mL/min/1.73 m stages 3-5 CKD or abnormal serum Cr/BUN levels had normal kidney ultrasound results. Some kidney ultrasound findings, such as renal stones or cysts, may not directly predict a risk of developing renal failure. Using the aMDRD eGFR equation, we found that 10.1% of study subjects had stages 3-5 CKD. We found that 734 (48.7%) subjects with stage 3 CKD had normal results for serum Cr and BUN, urinalysis and kidney ultrasound. Moreover, significant episodes of renal failure requiring dialysis were found among the 4.6% of subjects who were classified as under-recognized. Taiwan has the largest end-stage renal disease population in the world, and therefore, early identification of CKD (e.g. via the application of the aMDRD eGFR equation) is very important. 4 A nationally representative survey from Taiwan in 2002 showed that the prevalence of stages 3-5 CKD in Taiwan was 6.9%. 4 However, the awareness rates for CKD in Taiwan were very low, being only 8% in stage 3 CKD. The low awareness rate was closely related to serum Cr levels. Subjects with serum Cr levels greater than 1.6 mg/dL (> 141 μmol/L) were more likely to be informed that they have kidney disease. 4 Another large-scale prospective cohort study based on 462,293 adults in Taiwan also reported a high prevalence of CKD and its associated all-cause mortality. 5 It also reported a significant lack of awareness of CKD among the study subjects in a standard medical screening program run by a private health management institution in Taiwan.
We found that all subjects with stages 4 and 5 CKD identified via the aMDRD equation had abnormal serum Cr levels and were identified as having kidney disease. For subjects with stage 4 or 5 CKD, many nonnephrologists may underestimate the disease status of CKD and fail to prevent the episode of acute or chronic renal disease. The low-limit values of serum Cr in subjects with stage 3 CKD for males and females were 1.3 mg/dL and 1.0 mg/dL, respectively. Both values overlapped the upper limit of normal for serum Cr level, which is 1.4 mg/dL. This finding challenges the traditional upper normal limit value for serum Cr. Further studies by separate gold standards such as iothalamate clearance or inulin clearance may help to adjust the normal range for serum Cr in Taiwanese.
Even if the routine clinical assessment tools for kidney disease are combined, a significant percentage of under-recognized CKD and a risk of renal failure were still reported in the current study. Episodes of renal failure within 2 years after standard medical screening may not be the best way to evaluate the accuracy of the eGFR equation or the routine assessment in health management centers. Although we failed to evaluate changes in serum Cr or eGFR in this large cohort, episodes of renal failure vary in different stages of CKD. Subjects with stage 3 CKD and normal routine clinical assessments had a higher risk of developing renal failure requiring dialysis compared with subjects with at least 1 abnormal routine clinical assessment. In particular, subjects with stage 3B CKD and normal routine clinical assessments may have the highest risk of developing renal failure requiring dialysis within 2 years. One possible explanation is that most clinicians may neglect the risk of renal injury induced by nephrotoxic drugs or procedures in patients with stage 3 CKD when they have had a normal renal function survey by serum Cr and BUN, urinalysis, and kidney ultrasound. There is growing evidence to suggest that patients with stage 3B have a higher risk of cardiovascular disease and rapid renal function progression compared with stage 3A patients. [18] [19] [20] [21] [22] Some limitations of this study should be noted. First, the relatively very small number of subjects with stage 3B CKD with normal routine clinical assessment may have had an impact on episodes of renal failure. Second, the definition of renal failure requiring dialysis was based on episodes of both acute and chronic renal failure requiring dialysis within 2 years after standard medical screening by review of medical records and interviews by phone. Potential errors from the phone interviews may also have limited the generalizability of the results.
The eGFR equation is not widely used in most clinical practices beyond nephrology in Taiwan, including most standard medical screening programs of health management centers. Our findings provide strong evidence for using the aMDRD eGFR equation as a routine assessment for CKD. In agreement with increasingly more international organizations, we have established an automatic eGFR reporting system by clinical laboratory in our hospital whenever serum Cr is measured to facilitate early recognition of CKD and to reduce the potential risk of nephrotoxic drugs or procedures. [23] [24] [25] There remains a lack of clarity in the definition of abnormal routine clinical assessment and its clinical significance in CKD classification for stages 3, 3A and 3B. In particular, abnormal laboratory findings are mainly due to non-renal problems, such as hematuria due to extra-renal origin, pyuria due to lower urinary tract infection and occult blood due to pigmenturia (hemoglobin or myoglobin), as well as renal cysts, stones, nodules or calcification, and change in kidney size with interference with kidney function. However, we failed to further reanalyze these factors in stage 3 CKD.
Accordingly, patients with stage 3 CKD were arbitrarily classified into only 2 groups (with or without normal routine clinical assessment), and this could have led to overestimating patient numbers in the 2 subgroups, in terms of stages 3A (n = 606) and 3B (n = 167) CKD with abnormal routine clinical assessment. Therefore, the crude rate of renal failure necessary for dialysis could have been exaggerated in stages 3A (1.7%) and 3B (20%) CKD with normal routine clinical assessment. We also failed to reclassify the subgroups in stages 3A and 3B CKD patients and reanalyze the crude rate of renal failure progression.
In conclusion, in the current large-cohort study, we found an apparent disagreement in identifying stage 3 CKD between routine clinical assessment tools and the aMDRD eGFR equation in a standard medical screening program. The significantly higher risk of renal failure in under-recognized stage 3B CKD suggests the value of using the eGFR equation in a health management institution and general clinical practice, especially in countries with a high prevalence of CKD such as Taiwan.
